黄钟花醌 | 84-79-7

• 物质功能分类: 有机原料 - 醌类化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 黄钟花醌
• 中文别名: 拉帕醇；拉帕酚；拉帕酸；五加酚
• 英文名称: Lapachol
• 英文别名: 2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthalenedione；2‐hydroxy‐3‐(3‐methyl‐2‐butenyl‐)‐1,4‐naphthoquinone；2-hydroxy-3-(3‘-methyl-2’-butenyl)-1,4-naphthoquinone；2-hydroxy-3-(3’-methyl-2’-butenyl)-1,4-naphthoquinone；2-hydroxy-3-(3′-methyl-2′-butenyl)-1,4-naphthoquinone；2-hydroxy-3-(3-methyl-2-butenyl)-1,4-dihydro-1,4-naphthalenedione
• CAS: 84-79-7
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: CIEYTVIYYGTCCI-UHFFFAOYSA-N

物化性质

• 熔点：
  141-143 °C(lit.)
• 沸点：
  325.09°C (rough estimate)
• 密度：
  1.2077 (rough estimate)
• 溶解度：
  在乙醇中的溶解度为10mg/mL，澄清，淡黄色至黄色
• LogP：
  2.516 (est)
• 稳定性/保质期：
  在常温常压下稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  3.23
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  54.37
• 氢给体数：
  1.0
• 氢受体数：
  3.0

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• RTECS号：
  QL8750000
• 海关编码：
  2914690090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  常温下应存放在阴凉干燥处。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Lapachol
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 84-79-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Inhalation (Category 4), H332
Acute toxicity, Dermal (Category 4), H312
Acute toxicity, Oral (Category 4), H302
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R20/21/22, R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H312 Harmful in contact with skin.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H332 Harmful if inhaled.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ protective clothing.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : Natural Yellow 16
2-Hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone
Formula : C15H14O3
Molecular Weight : 242,27 g/mol
CAS-No. : 84-79-7
EC-No. : 201-563-7
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Hydroxy-3-(3-methylbut-2-enyl)-1,4-naphthoquinone
CAS-No. 84-79-7 Acute Tox. 4; Skin Irrit. 2; Eye <= 100 %
EC-No. 201-563-7 Irrit. 2; STOT SE 3; H302,
H312, H315, H319, H332,
H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Hydroxy-3-(3-methylbut-2-enyl)-1,4-naphthoquinone
CAS-No. 84-79-7 Xn, R20/21/22 - R36/37/38 <= 100 %
EC-No. 201-563-7
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 141 - 143 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
LD50 Oral - mouse - 487 mg/kg
Remarks: Behavioral:Somnolence (general depressed activity). Diarrhoea Prolonged skin contact may
cause skin irritation and/or dermatitis.
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: QL8750000
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Eye Irrit. Eye irritation
H302 Harmful if swallowed.
H312 Harmful in contact with skin.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H332 Harmful if inhaled.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R20/21/22 Harmful by inhalation, in contact with skin and if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

生物活性

Lapachol 是一种萘醌，最初从紫葳科的 Tabebuia avellanedae 中分离得到。它具有多种生物活性，包括抗脓肿、抗溃疡、抗真菌、抗癌、抗血毒、抗炎、抗疟疾、防腐、抗肿瘤、抗病毒、抗菌和杀虫作用。

生产方法

Lapachol 通常通过二元酚、酚类和芳胺的氧化反应制备。

反应信息

• 作为反应物：
  描述：

  黄钟花醌 在 盐酸 、 溶剂黄146 作用下， 以 水 为溶剂， 以95%的产率得到ALPHA-拉杷醌
  参考文献：
  名称：

  On the investigation of hybrid quinones: synthesis, electrochemical studies and evaluation of trypanocidal activity

  摘要：

  三十八种化合物被评估对抗克氏锥虫，其中六种被发现对游离子比苯硝唑更有效。

  DOI：

  10.1039/c5ra16213k
• 作为产物：
  描述：

  2-甲氧基-1,4-萘醌 在 sodium carbonate 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 24.83h， 生成 黄钟花醌
  参考文献：
  名称：

  Kapoor, N. K.; Gupta, R. B.; Khanna, R. N., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1982, vol. 21, # 3, p. 189 - 191

  摘要：

  DOI：

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2015135094A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及作为一个或多个组蛋白去甲基化酶抑制剂的化合物。该发明还提供了包括本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2017205538A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.

  本发明涉及一种化合物公式（I）及其盐，其中R1、R2X和Y具有本文中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病，如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。
• [EN] PROTAC ANTIBODY CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS ANTICORPS-PROTAC ET PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2017201449A1

  公开（公告）日：2017-11-23

  The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

  本主题描述的是抗体-PROTAC偶联物（PACs），包含它们的药物组合物，以及它们在治疗那些有靶向蛋白质降解有益的疾病和状况中的用途。
• Lawsone, Juglone, and β-Lapachone Derivatives with Enhanced Mitochondrial-Based Toxicity
  作者：Laura Anaissi-Afonso、Sandra Oramas-Royo、Jessel Ayra-Plasencia、Patricia Martín-Rodríguez、Jonay García-Luis、Isabel Lorenzo-Castrillejo、Leandro Fernández-Pérez、Ana Estévez-Braun、Félix Machín

  DOI：10.1021/acschembio.8b00306

  日期：2018.8.17

  Saccharomyces cerevisiae for several derivatives of three important natural naphthoquinones: lawsone, juglone, and β-lapachone. We have found that (i) the free hydroxyl group of lawsone and juglone modulates toxicity; (ii) lawsone and juglone derivatives differ in their mechanisms of action, with ROS generation being more important for the former; and (iii) a subset of derivatives possess the capability to disrupt

  萘醌是从植物和微生物中获得的最活跃的天然产物之一。萘醌通过多效机制发挥其生物活性，包括对细胞亲核试剂的反应性、活性氧 (ROS) 的产生和蛋白质的抑制。在这里，我们报告了在酿酒酵母中进行的机械抗增殖研究对于三种重要的天然萘醌的几种衍生物：指甲花醌、胡桃醌和 β-拉帕醌。我们发现 (i) 胡桃醌和胡桃醌的游离羟基可调节毒性；(ii) 指甲花醌和胡桃醌衍生物的作用机制不同，活性氧的产生对前者更为重要；(iii) 一部分衍生物具有破坏线粒体功能的能力，在这方面，β-拉帕酮是最有效的化合物。此外，我们将酵母结果与抗菌和抗肿瘤活性进行了交叉比较。我们讨论了萘醌的机理发现、抗增殖活性和物理化学性质之间的关系。
• Synthesis and Biological Evaluation of Lipophilic 1,4-Naphthoquinone Derivatives against Human Cancer Cell Lines
  作者：Shao-Hung Wang、Chih-Yu Lo、Zhong-Heng Gwo、Hong-Jhih Lin、Lih-Geeng Chen、Cheng-Deng Kuo、Jin-Yi Wu

  DOI：10.3390/molecules200711994

  日期：——

  these cell lines. Our results showed that the effectiveness of compound 11a may be attributed to its suppression of the survival of HT-29. Secondly, in the Hoechst 33258 staining test, compound 11a-treated cells exhibited nuclear condensation typical of apoptosis. Additionally, cell cycle analysis by flow cytometry indicated that compound 11a arrested HT-29 cells in the S phase. Furthermore, cell death

  为了检查疏水性对 1,4-萘醌衍生物抗癌活性的影响，合成并评估了一系列带有 2-O-烷基-、3-C-烷基-或 2/3-N-吗啉代烷基的化合物因其在体外对五种人类癌细胞系的抗癌活性。通过 MTT 测定法测定了这些衍生物对 HT-29、SW480、HepG2、MCF-7 和 HL-60 细胞的细胞毒性。其中，2-hydroxy-3-farnesyl-1,4-naphthoquinone (11a) 被发现对这些细胞系的细胞毒性最强。我们的结果表明，化合物 11a 的有效性可能归因于其抑制 HT-29 的存活。其次，在 Hoechst 33258 染色试验中，化合物 11a 处理的细胞表现出典型的细胞凋亡的核凝聚。此外，通过流式细胞术进行的细胞周期分析表明，化合物11a 在S 期阻止了HT-29 细胞。此外，通过膜联蛋白 V-FITC/碘化丙啶染色检测的细胞死亡表明，化合物 11a 以浓度依赖性方式有效诱导

表征谱图